נבלבין 20 מג ישראל - עברית - Ministry of Health

נבלבין 20 מג

padagis israel agencies ltd, israel - vinorelbine as tartrate - קפסולות - vinorelbine as tartrate 20 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.

אטופוסיד אבווה 20 מגמל ישראל - עברית - Ministry of Health

אטופוסיד אבווה 20 מגמל

novartis israel ltd - etoposide - תרכיז להכנת תמיסה לאינפוזיה - etoposide 20 mg/ml - etoposide - etoposide - small cell lung cancer, resistant non-seminomatous testicular carcinoma, hodgkin's and non-hodgkin's lymphoma, acute myelocytic leukemia.

דוקסורוביצין טבע ישראל - עברית - Ministry of Health

דוקסורוביצין טבע

abic marketing ltd, israel - doxorubicin hydrochloride - תרכיז להכנת תמיסה לאינפוזיה - doxorubicin hydrochloride 2 mg/ml - doxorubicin - doxorubicin - to produce regression in disseminated neoplastic conditions such as: - acute lymphoblastic leukemia, - acute myeloblastic leukemia, - wilms' tumor neuroblastoma, - soft tissue and bone sarcomas, - breast carcinoma, - lymphomas of both hodgkin's and non-hodgkin's types, - bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types, - gastric carcinoma.

דוקסורוביצין אבווה 2 מגמל ישראל - עברית - Ministry of Health

דוקסורוביצין אבווה 2 מגמל

novartis israel ltd - doxorubicin hydrochloride - solution for infusion - doxorubicin hydrochloride 2 mg/ml - doxorubicin - doxorubicin - soft tissue and bone sarcomas, hodgkin's and non-hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloblastic leukemia, wilms` tumor, carcinomas of the thyroid, breast, ovary, bladder, small cell bronchogenic carcinoma and neuroblastoma.

3DHD VISION SYSTEM ישראל - עברית - Ministry of Health

3dhd vision system

ש. שיווק כל מילניום בע"מ - מומחה - המערכת מאפשרת קבלת תמונה תלת מימדית רציפה ברזולוציה גבוהה לניתוחים לפורסקופיים

אדסטריס 50 מג ישראל - עברית - Ministry of Health

אדסטריס 50 מג

takeda israel ltd - brentuximab vedotin - אבקה להכנת תמיסה מרוכזת לעירוי - brentuximab vedotin 50 mg/vial - brentuximab vedotin

מבטרה 1400 מג S.C ישראל - עברית - Ministry of Health

מבטרה 1400 מג s.c

roche pharmaceuticals (israel) ltd - rituximab - תמיסה להזרקה - rituximab 1400 mg / 11.7 ml - rituximab

ריקסתון ישראל - עברית - Ministry of Health

ריקסתון

novartis israel ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg / 1 ml - rituximab

רקורמון 2000 IU ישראל - עברית - Ministry of Health

רקורמון 2000 iu

roche pharmaceuticals (israel) ltd - epoetin beta 2000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

רקורמון IU 3000 ישראל - עברית - Ministry of Health

רקורמון iu 3000

roche pharmaceuticals (israel) ltd - epoetin beta 3000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative